ADRX Andrx Group
Andrx Group (ADRX) is expected to report earnings on February 11, 2027, after the market close. The consensus earnings estimate is a loss of $0.36 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -6.4% since its last earnings release on November 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Andrx Group
Andrx Corp. formulates and commercializes controlled-release oral pharmaceuticals using their proprietary drug delivery technologies. Through Andrx Corp.'s distribution operations, they sell generic drugs manufactured by third parties primarily to pharmacies which do not maintain their own central warehousing facilities and pharmacy buying groups. Through their Cybear subsidiary, Andrx Corp. develops Internet applications to improve the efficiency of administrative and communications tasks for companies in health care industry.
Industry
Drug Delivery
Charts powered in part by Lightweight Charts™ by TradingView.